Tumor-suppressing multi-enterobacteria and PD-1/PD-L1 immune checkpoint inhibitor combination improves the outcome of hepatocellular carcinoma therapy

ObjectiveProgrammed death 1 (PD-1) and its ligand PD-L1 inhibitors and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibodies have been approved for the treatment of advanced hepatocellular carcinoma (HCC), but the response rates of these immunotherapy are not high, and they are...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Dongjuan Wu, Yaohua Fan, Mingsheng Zhang, Xiaoguang Wang, Xuesong He, Xinwei Guo, Yangchen Liu, Chenxi Cao, Zhaoqun Deng
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Frontiers Media S.A. 2025-06-01
Σειρά:	Frontiers in Immunology
Θέματα:	tumor-suppressing multi-enterobacteria hepatocellular carcinoma intestinal microbiota tumor immune microenvironment anti-programmed death-1 monoclonal antibody anti-programmed death ligand-1 (PD-L1) monoclonal antibody
Διαθέσιμο Online:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1598436/full
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!